AngioDynamics (ANGO) Tops Q3 EPS by 4c; Adjusted FY17 Revs Lower, EPS Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AngioDynamics Reports Fiscal 2017 Third Quarter Results
March 30, 2017 6:00 AM EDTQ3 net sales of $85.6 million, down 2% year-over-yearQ3 GAAP earnings per share of $0.08; non-GAAP adjusted EPS up 27% from Q3 fiscal 2016 Q3 operating cash generation of $14.4 million; free cash flow generation of $14.0 millionRevised FY2017 revenue and adjusted EPS guidance; free cash flow guidance unchanged
ALBANY, N.Y., March 30, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported financial results for the 2017 fiscal year third quarter... More
